Cargando…
P907: CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB (KDD) VS CARFILZOMIB AND DEXAMETHASONE (KD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): FRAILTY SUBGROUP ANALYSIS OF THE CANDOR STUDY
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429219/ http://dx.doi.org/10.1097/01.HS9.0000846500.86746.52 |
| _version_ | 1784779371325685760 |
|---|---|
| author | Quach, H. Leleu, X. Mateos, M.-V. Usmani, S. Z. Nooka, A. K. Goldrick, A. Najdi, R. Shu, N. Facon, T. |
| author_facet | Quach, H. Leleu, X. Mateos, M.-V. Usmani, S. Z. Nooka, A. K. Goldrick, A. Najdi, R. Shu, N. Facon, T. |
| author_sort | Quach, H. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9429219 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94292192022-08-31 P907: CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB (KDD) VS CARFILZOMIB AND DEXAMETHASONE (KD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): FRAILTY SUBGROUP ANALYSIS OF THE CANDOR STUDY Quach, H. Leleu, X. Mateos, M.-V. Usmani, S. Z. Nooka, A. K. Goldrick, A. Najdi, R. Shu, N. Facon, T. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9429219/ http://dx.doi.org/10.1097/01.HS9.0000846500.86746.52 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Quach, H. Leleu, X. Mateos, M.-V. Usmani, S. Z. Nooka, A. K. Goldrick, A. Najdi, R. Shu, N. Facon, T. P907: CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB (KDD) VS CARFILZOMIB AND DEXAMETHASONE (KD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): FRAILTY SUBGROUP ANALYSIS OF THE CANDOR STUDY |
| title | P907: CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB (KDD) VS CARFILZOMIB AND DEXAMETHASONE (KD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): FRAILTY SUBGROUP ANALYSIS OF THE CANDOR STUDY |
| title_full | P907: CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB (KDD) VS CARFILZOMIB AND DEXAMETHASONE (KD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): FRAILTY SUBGROUP ANALYSIS OF THE CANDOR STUDY |
| title_fullStr | P907: CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB (KDD) VS CARFILZOMIB AND DEXAMETHASONE (KD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): FRAILTY SUBGROUP ANALYSIS OF THE CANDOR STUDY |
| title_full_unstemmed | P907: CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB (KDD) VS CARFILZOMIB AND DEXAMETHASONE (KD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): FRAILTY SUBGROUP ANALYSIS OF THE CANDOR STUDY |
| title_short | P907: CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB (KDD) VS CARFILZOMIB AND DEXAMETHASONE (KD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): FRAILTY SUBGROUP ANALYSIS OF THE CANDOR STUDY |
| title_sort | p907: carfilzomib, dexamethasone, and daratumumab (kdd) vs carfilzomib and dexamethasone (kd) in relapsed/refractory multiple myeloma (rrmm): frailty subgroup analysis of the candor study |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429219/ http://dx.doi.org/10.1097/01.HS9.0000846500.86746.52 |
| work_keys_str_mv | AT quachh p907carfilzomibdexamethasoneanddaratumumabkddvscarfilzomibanddexamethasonekdinrelapsedrefractorymultiplemyelomarrmmfrailtysubgroupanalysisofthecandorstudy AT leleux p907carfilzomibdexamethasoneanddaratumumabkddvscarfilzomibanddexamethasonekdinrelapsedrefractorymultiplemyelomarrmmfrailtysubgroupanalysisofthecandorstudy AT mateosmv p907carfilzomibdexamethasoneanddaratumumabkddvscarfilzomibanddexamethasonekdinrelapsedrefractorymultiplemyelomarrmmfrailtysubgroupanalysisofthecandorstudy AT usmanisz p907carfilzomibdexamethasoneanddaratumumabkddvscarfilzomibanddexamethasonekdinrelapsedrefractorymultiplemyelomarrmmfrailtysubgroupanalysisofthecandorstudy AT nookaak p907carfilzomibdexamethasoneanddaratumumabkddvscarfilzomibanddexamethasonekdinrelapsedrefractorymultiplemyelomarrmmfrailtysubgroupanalysisofthecandorstudy AT goldricka p907carfilzomibdexamethasoneanddaratumumabkddvscarfilzomibanddexamethasonekdinrelapsedrefractorymultiplemyelomarrmmfrailtysubgroupanalysisofthecandorstudy AT najdir p907carfilzomibdexamethasoneanddaratumumabkddvscarfilzomibanddexamethasonekdinrelapsedrefractorymultiplemyelomarrmmfrailtysubgroupanalysisofthecandorstudy AT shun p907carfilzomibdexamethasoneanddaratumumabkddvscarfilzomibanddexamethasonekdinrelapsedrefractorymultiplemyelomarrmmfrailtysubgroupanalysisofthecandorstudy AT facont p907carfilzomibdexamethasoneanddaratumumabkddvscarfilzomibanddexamethasonekdinrelapsedrefractorymultiplemyelomarrmmfrailtysubgroupanalysisofthecandorstudy |